Edwards Rises to 418th in Market Activity as Structural Heart Innovations Bolster Leadership

On August 29, 2025, Edwards (NYSE: EW) rose 0.14% as trading volume dropped 20.81% to $220 million, ranking 418th in market activity. The stock’s muted performance contrasts with broader market trends, reflecting a focus on sector-specific catalysts.

Edwards welcomed the updated ESC/EACTS guidelines for valvular heart disease, which establish a streamlined care pathway for severe aortic stenosis (AS) patients, including asymptomatic cases. The guidelines lower the age threshold for TAVR to 70, aligning with Edwards’ leadership in the space. The company holds exclusive US and EU approvals for TAVR in asymptomatic severe AS, supported by the EARLY TAVR trial and recent CE Mark for its SAPIEN 3 Ultra RESILIA platform. The updated protocols emphasize proactive intervention, shifting away from passive monitoring and reinforcing Edwards’ evidence-based approach.

Additional momentum comes from the EVOQUE transcatheter tricuspid valve replacement (TTVR) system. Data from the TRISCEND II study demonstrated EVOQUE’s 18-month reduction in heart failure hospitalizations for severe tricuspid regurgitation patients and superior 1-year outcomes compared to medical therapy alone. As the first and only approved TTVR system in the US and EU, EVOQUE’s performance underscores Edwards’ innovation in structural heart disease. The company’s CEO highlighted these developments as strategic wins, enhancing patient access and healthcare system efficiency.

Edwards’ market position is reinforced by its SAPIEN platform, which has treated over 1 million patients since its launch. The guidelines’ emphasis on transcatheter therapies for mitral and tricuspid valves further positions the firm to benefit from expanded indications and adoption. With a robust pipeline and guideline alignment, the company remains a key player in advancing structural heart care.